Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Melanotan I (afamelanotide) regulatory status

Current status of Melanotan I (afamelanotide) in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of Melanotan I (afamelanotide)?

Regulatory: FDA approvedWADA: Not WADA prohibitedVerified: Verified Sep 23, 2026
FDA and compounding
FDA approved as Scenesse (afamelanotide) implant on October 8, 2019, for adults with a history of phototoxic reactions from erythropoietic protoporphyria; the European Medicines Agency approved it in 2014. It is dispensed only through certified specialist centers because insertion requires training. Afamelanotide is not on any 503A or 503B bulks list; as the active ingredient of an approved drug it could in principle be compounded in another dosage form, but injectable Melanotan I sold online for tanning is not a compounded prescription product and is an unapproved drug.
WADA
Not WADA prohibited
Access path
  1. Prescription from a specialist in erythropoietic protoporphyria at a certified treatment center (Scenesse implant).
  2. Not available for tanning or cosmetic use through any licensed channel.
  3. Products sold online as Melanotan I injections are unapproved drugs and are not verified for purity.

Full Melanotan I (afamelanotide) page: evidence, dosing in the literature, and sources

How has the status of Melanotan I (afamelanotide) changed over time?

  1. FDA

    FDA approves Scenesse (afamelanotide) for erythropoietic protoporphyria

    FDA approved afamelanotide implant (Scenesse) to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. Afamelanotide is the only approved melanotan-class peptide.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Melanotan I (afamelanotide) and the source of each dated event.

  1. [1]FDA prescribing information for Scenesse (afamelanotide) implant, via DailyMedFDA, 2026
  2. [2]FDA: Compounding and the FDA, questions and answersFDA, 2026
  3. [3]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list and withdrawn nominations, current as of April 22, 2026)FDA, 2026
  4. [4]WADA Prohibited ListWADA, 2026
  5. [5]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  6. [6]Drugs@FDA: Scenesse (afamelanotide) NDA 210797FDA, 2019

From the blog